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Abstract 
We report the largest international study on Glanzmann thrombasthenia (GT), an inherited 
bleeding disorder where defects of the ITGA2B and ITGB3 genes cause quantitative or 
qualitative defects of the αIIbβ3 integrin, a key mediator of platelet aggregation. Sequencing 
of the coding regions and splice sites of both genes in members of 76 affected families 
identified 78 genetic variants (55 novel) suspected to cause GT. Four large deletions or 
duplications were found by quantitative real-time PCR. Families with mutations in either 
gene were indistinguishable in terms of bleeding severity that varied even among siblings. 
Families were grouped into type I and the rarer type II or variant forms with residual αIIbβ3 
expression. Variant forms helped identify genes encoding proteins mediating integrin 
activation. Splicing defects and stop codons were common for both ITGA2B and ITGB3 and 
essentially led to a reduced or absent αIIbβ3 expression; included was a heterozygous 
c.1440-13_c.1440-1del in intron 14 of ITGA2B causing exon skipping in 7 unrelated 
families. Molecular modeling revealed how many missense mutations induced subtle changes 
in αIIb and β3 domain structure across both subunits thereby interfering with integrin 
maturation and/or function. Our study extends knowledge of Glanzmann thrombasthenia and 
the pathophysiology of an integrin. 
 
Keywords: Glanzmann thrombasthenia; ITGA2B; ITGB3; integrin αIIbβ3; molecular 
modeling 
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Introduction 
 
Glanzmann thrombasthenia (GT; MIM# 273800) is an inherited rare bleeding syndrome 
caused by an absence of platelet aggregation. Although platelets recruit to sites of vessel 
injury, they fail to spread or form the platelet-to-platelet bonds essential for thrombus build 
up [George et al., 1990; Coller and Shattil, 2008; Nurden et al., 2011]. The molecular basis of 
GT is an absence or severe deficiency of the αIIbβ3 integrin (formerly designated the GPIIb-
IIIa complex). Rare variant forms are given by qualitative defects of normally or partially 
expressed integrin while low platelet numbers and increases in platelet size are occasionally 
seen [Nurden et al., 2011; 2013]. Clot retraction and endocytosis of platelet-bound fibrinogen 
(Fg) to α-granules are frequently defective but can be retained in patients with residual 
αIIbβ3. While aggregation is mediated by activation-dependent binding of Fg to αIIbβ3, 
another mechanism and different amino acids are responsible for platelet attachment to fibrin 
[Podolnikova et al., 2014]. 
The ITGA2B (MIM# 607759) and ITGB3 (MIM# 173470) genes closely localize on 
chromosome 17 and code for αIIbβ3 [Wilhide et al., 1997]. Although αIIb is mainly 
exclusive to the megakaryocyte (MK) lineage, β3 is widely distributed in tissues associated 
with αv as the vitronectin receptor. Transcripts for αIIb and β3 are present early in MK 
development with αIIb synthesized as a pro-peptide [Mitchell et al., 2006]. Ca2+-dependent 
complex formation between pro-αIIb and β3 is a key early step; the integrin then undergoes a 
series of O- and N-glycosylations and posttranslational modifications in the endoplasmic 
reticulum (ER) and the Golgi apparatus. The mature subunits have single transmembrane 
domains and short cytoplasmic tails that have a salt-link between β3D723 and αIIbR995 as 
well as interactions with cytoskeletal and cytoplasmic proteins including talin and kindlin-3 
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[Yang et al., 2009]. Like other integrins, αIIbβ3 can mediate bidirectional signaling [Shattil 
and Newman, 2004; Coller and Shattil, 2008]. 
Major structural extracellular features of αIIb include the N-terminal β-propeller 
followed by the thigh, calf-1 and calf-2 domains; whereas for β3 the N-terminal PSI 
(plexin/semaphorin/integrin) domain is followed by hybrid,βI (βA), disulfide-rich EGF 
(epidermal growth factor) and membrane proximal β-tail domains [Xiao et al., 2004; Eng et 
al., 2011]. βI domain contains the functionally important MIDAS (metal ion-dependent 
adhesion site), ADMIDAS (adjacent to MIDAS) and SYMBS (synergistic metal binding 
site). Crystallography showed resting αIIbβ3 in a bent structure that straightens on platelet 
activation in parallel with exposure of determinants that bind Fg and other adhesive ligands to 
the headpiece [Zhu et al., 2013]. Nevertheless, the classical concept of a bent “non-activated” 
integrin has recently been challenged [Choi et al., 2013].  
GT is caused by nonsyndromic genetic variants across both ITGA2B (30 exons) and 
ITGB3 (15 exons) (D’Andrea et al., 2002; Peretz et al., 2006; Kannan et al., 2009; Jallu et al., 
2010; Nurden et al., 2011; 2013). Approximately 200 mutations are currently found on the 
GT database (http://sinaicentral.mssm.edu/intranet/research/glanzmann/menu). Mutations 
include splice defects and stop codons that interfere with or abrogate mRNA synthesis while 
small deletions (del) and insertions (ins) with frameshifts are common. Large gene deletions 
are rare [Burk et al., 1991; Djaffar et al., 1993; Rosenberg et al., 1997]. Mostly, they affect 
αIIbβ3 synthesis or maturation; however missense mutations allowing partial or normal 
αIIbβ3 expression have helped identify functional domains [Loftus et al., 1990; Bajt et al., 
1992; Chen et al., 1992]. Although mutations affecting β3 are predicted to extend to other 
tissues, mucocutaneous bleeding is the predominant characteristic of GT [George et al., 1990; 
Seligsohn, 2012].  
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We now report gene screening for 76 families with GT in much the largest study to be 
reported; results were compared to phenotype and bleeding severity. Sanger sequencing 
identified 78 potentially pathological mutations (55 novel) spread across both genes while 
quantitative PCR identified 4 large deletions or duplications. In silico modeling enabled an 
assessment of the effects of novel amino acid substitutions on αIIbβ3 structure. This 
international study considerably extends current knowledge of the molecular basis of GT. 
 
Patients, Material and Methods 
 
Patient selection 
Genotyping was initially offered to GT patients in France under the terms of a contract 
(N°132/AP 2007-2008) between the French National Platelet Reference Center (Dr. P. 
Nurden, Bordeaux) and the Genomics Institute of the Commissariat à l’Energie Atomique 
(Professor J Weissenbach, Genoscope, Evry). This involved sequencing the ITGA2B genes 
and the ITGB3 genes for 90 patients. The study was subsequently opened on a random 
international basis (Argentina, Canada, Morocco, Spain, Switzerland, USA) until the 90 
patients were obtained.  In the final analysis we include 76 families representing 83 cases. 
From the original 90 patients, two were withdrawn when the original diagnosis of GT was not 
confirmed while for 5 patients the isolated DNA either failed quality control or the patients 
were unavailable for necessary follow-up studies. Written informed consent was obtained for 
DNA sequencing according to the laws of the country and the study performed under the 
promotion of the Ethics Committee of the French National Institute of Health and Medical 
Research (INSERM: RBM 01-14). Patient inclusion was based on a history of 
mucocutaneous bleeding: major symptoms include epistaxis, easy bruising, hematomas, 
ecchymoses, petechiae, gingivorrhagia, heavy bleeding at menarche and menometrorrhagia, 
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post-partum hemorrhage, gastrointestinal (GI) bleeding, post-invasive bleeding; all symptoms 
typical of GT [George et al., 1990; Seligsohn, 2012]. Also required was an absent or a 
severely decreased platelet aggregation with at least 3 agonists (e.g. ADP, collagen and 
thrombin receptor activating peptide (TRAP)) and a normal or cyclical GPIb-dependent 
ristocetin-induced platelet agglutination. An absent or severely reduced platelet expression of 
αIIbβ3 in flow cytometry and/or after detection of the two subunits by Western blotting (WB) 
using SDS-soluble platelet extracts allowed definition of the type I (<5% αIIbβ3) and type II 
subgroups (5-25% αIIbβ3) [George et al., 1990]. In the case of qualitative defects of αIIbβ3, 
the requirement was an inability of ADP to induce the binding of Fg or PAC-1 (Becton 
Dickinson, New Jersey, USA) to platelets; PAC-1 recognizes an activation determinant close 
to the Fg-binding site. All platelet function tests were performed locally using the standard 
procedures of each Centre. A questionnaire was completed for each patient and included 
information on the patient’s age and sex, country of origin, consanguinity, history of the 
disease, whether other family members were affected (and if genetic testing had been 
performed), nature and frequency of bleeding, treatment and the presence or not of anti-
αIIbβ3 platelet antibodies (produced after transfusion or pregnancy when the patient’s 
immune system comes into contact with normal platelets). A summary of the clinical and 
biological data obtained for each patient is provided in Supp. Table S1. A World Health 
Organization (WHO) bleeding score was established retrospectively for each patient: Grade 
0, no bleeding; 1, mild petechial or minimal bleeding; 2, occasional significant bleeding 
requiring transfusion or recombinant FVIIa; 3, repeated episodes of bleeding requiring 
multiple transfusions or other treatments; 4, major or life threatening bleeding and 
hospitalizations [Bercovitz and O’Brien, 2012]. Data was assessed for statistical significance 
in selected groups using the two-sided Fisher's Exact Test.  
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DNA sequencing 
EDTA-anticoagulated whole blood or the leukocyte-rich buffy coat was used for DNA 
extraction in each Centre or using the QIamp DNA Blood Mini kit (Qiagen, Courtaboeuf, 
France) after being sent to Bordeaux or Lyon. Coded samples were sent to the Genoscope for 
sequencing (National DNA Sequencing Centre, Evry, France). Included were two patients 
(GT9 and GT10) for whom single heterozygous mutations had previously been detected by 
Sanger sequencing following single strand conformation polymorphism analysis (SSCP) [see 
Peyruchaud et al., 1998; Nurden et al., 2002] and for whom a second non-detected 
heterozygous mutation was presumed.  Technical details of our screening strategy and primer 
design, PCR conditions, sequencing analysis, the in silico analysis of genetic variants are to 
be found in Supp. Methods. Sanger sequencing ensured coverage of exons and splice sites of 
the ITGA2B and ITGB3 genes as well as untranslated regions (UTR). For ITGA2B we 
sequenced 416bp upstream of the promoter and for ITGB3 463bp upstream. High-resolution 
melting curve analysis (HRM) was performed as described [Fiore et al., 2011].  
 
Nomenclature 
Human Genome Variation Society (HGVS) nomenclature is used throughout for cDNA and 
protein numbering unless otherwise stated. For nucleotide numbering, the A nucleotide of the 
ATG start codon was designated +1 (cDNA ITGA2B and ITGB3 GenBank accession numbers 
NM_000419.3 and NM_000212.2, respectively). For amino acid numbering +1 corresponds 
to the initiating Met with signal peptide included. However, as the numbering for the mature 
protein was used for the crystal structure of αIIbβ3 [see Xiao et al. 2004; Zhu et al. 2013], 
HGVS nomenclature is followed by mature protein numbering (in parentheses) in sections 
showing the influence of missense mutations on protein structure. This involves subtracting 
31 amino acids from the HGVS numbering of αIIb and 26 amino acids for β3. 
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Minigene constructions and splicing analysis 
Minigene constructs containing a genomic fragment spanning from the exon upstream to the 
exon downstream of the exon under study were synthesized by Epoch Life Science (Missouri, 
TX) and cloned into the Exontrap plasmid (MoBiTec GmbH, Goettingen, Germany). COS-7 
cells were grown at 8x104 cells/well in a 12-well plate with 1 ml of Dulbecco’s modified 
Eagle’s medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine 
serum, penicillin/streptomycin and 1M HEPES (Lonza, Verviers, Belgium) at 37°C in 5% 
CO2. Wild-type and mutant minigene constructs were transiently transfected into cells 24 h 
later using the jetPRIME transfection reagent according to the manufacturer’s instructions 
(Polyplus-transfection SAS, Strasbourg, France). Cells were then incubated for 48 h before 
isolation of total RNA using TRI Reagent (Molecular Research Center, Inc., Cincinnati, OH). 
cDNA was synthesized using 2 µg of RNA with the M-MLV reverse transcriptase kit 
(Promega corporation, WI, USA) and amplified with specific primers using different cycling 
programs (available on request). The amplified products were then resolved on 2% agarose 
gels and sequenced on a CEQ 8000 Genetic Analysis System using the CEQ DTCS Quick 
Start Kit (Beckman Coulter, Fullerton, CA, USA). Real-time PCR was carried out in a 
LightCycler 96 detection system (Roche Diagnostics, Mannheim, Germany) using 
intercalation of SYBR green as a fluorescence reporter. 
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Large gene deletions or duplications 
To identify large homozygous or heterozygous deletions, or duplications, we used a relative 
quantitative real-time PCR assay. This approach was applied to 3 groups of patients: those for 
whom sequencing the ITGA2B or ITGB3 genes revealed no genetic abnormality, a single 
heterozygous defect or a homozygous mutation but with no consanguinity described in the 
family. Exons of ITGB3 and ITGA2B genes were amplified in a single amplicon (excepting 
for exon 1 of ITGB3 which failed to amplify). Primers were designed using one-line primer-
blast software (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). PCR product sizes were 
about 200 bp. Melting curves were performed to verify the specificity of PCR products. 
Primer sequences and PCR protocols are available on request. Real time PCRs were 
performed on a Rotor-Gene 6000 cycler (Qiagen) in 20 µl volume, using QuantiTect® 
SYBR® Green PCR kit (Qiagen) with 5 ng of sample genomic DNA and 15 pmoles of each 
primer. First denaturation was performed at 95°C for 15 min, followed by 40 cycles (95°C for 
15 sec, annealing temperature at 60°C for 15 sec, and 72°C for 20 sec). PCR reactions were 
terminated by a post-extension step of 90 sec at 72°C followed by a melting curve from 60 to 
95°C (1 °C by step). Each patient was examined in triplicate in the same run. The relative 
amount of ITGA2B or ITGB3 was established as a ratio of the reference gene, a 188 bp PCR 
product of HMBS (hydroxymethylbilane synthase, 11q23.3). We used a 2 Standard Curves 
method (Rotor-Gene Q series software 1.7.94: 2 Standard Curves Relative Quantification). 
The relative concentration is 1 when there is no rearrangement; 0.5 for a heterozygous 
deletion; 1.5 for a heterozygous duplication; and 2 for a homozygous duplication. 
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Site-directed mutagenesis and expression in heterologous cells 
cDNAs of αIIb and β3 in pcDNA3 vectors were generously provided by Dr N. Rosenberg 
(Thrombosis and Hemostasis Institute, Sheba Medical Center, Israel). Mutations were 
introduced in full-length ITGA2B or ITGB3 cDNA with the QuickChange II XL site-directed 
mutagenesis kit (Agilent Technologies, Santa Clara, CA) according to the manufacturer’s 
instructions. COS-7 cells were cultured as described above. Cells were harvested 24 or 48 h 
after transfection and expression of cell surface αIIbβ3 assessed by flow cytometry with a 
Becton Dickinson (BD) Accuri™ C6 flow cytometer (BD Biosciences, Oxford, UK) using 
fluorescein isothiocyanate (FITC) conjugated anti-CD41/P2, anti-CD41/SZ22 (Beckman 
Coulter, Brea, CA), and anti-CD61 (Dako, Glostrup, Denmark) monoclonal antibodies 
(MoAbs) or as previously described by us [Milet-Marsal et al., 2002]. The activation state of 
recombinant αIIbβ3 was assessed by PAC-1 (BD Biosciences, Oxford, UK) binding after 
incubation of the cells with 1 mM MnCl2. Transfected COS-7 cells were lysed in buffer 
containing sodium dodecyl sulfate (SDS) according to our standard procedures. SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) was performed using 10% gradient gels, in 
the presence or absence of 1mM dithiothreitol and proteins transferred to nitrocellulose. 
Bands corresponding to αIIb and β3 were located using the MoAbs SZ22 (αIIb, Beckman 
Coulter) and Y2/51 (β3, Dako, Glostrup, Denmark), with bound IgG assessed by 
chemiluminescence using peroxidase-linked anti-mouse IgG.  
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Protein Modeling 
Models were constructed using the PyMol Molecular Graphics System, version 1.3, 
Schrödinger, LLC (www.pymol.org) and 3fcs or 2vdo pdb files for crystal structures of 
IIb3 in the bent or extended conformations and 2knc pdb files for transmembrane and 
cytosolic domains as described in our previous publications [Nurden et al., 2011; 2013]. 
Amino acid changes are visualized in the rotamer form showing side change orientations 
incorporated from the Dunbrack Backbone library with the maximum probability.  
 
Molecular dynamics simulations 
These were performed as described by us [Laguerre et al., 2013]. Briefly, our procedure starts 
from the X-ray structure of αIIbβ3 with pdb code 3NIG (resolution 2.25 Å) using αIIbβ3 
truncated at membrane proximal domains. Calculations were accomplished using 
GROMACS 4.5 and the GROMOS96 force field (G43a1) packages. Molecular dynamics 
runs were performed at constant temperature and pressure with a Berendsen coupling 
algorithm [Laguerre et al., 2013]. The αIIb mutant p.Gly44Val was created via the 
appropriate module in Discovery Studio version 3.1. In trajectory analyses root mean square 
deviations (RMSD) were calculated on Calpha positions. 
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Results 
Patients’ phenotype 
The phenotypes of 83 GT patients grouped within 76 families are given in Supp. Table S1. 
The majority of families (58) have type I GT with <5% αIIbβ3 on their platelets. In 
agreement with the report of 64 cases by George et al. [1990], lesser but significant 
subpopulations of families have type II (9 families; 5 to 25% αIIbβ3) or potential variant 
forms with qualitative defects (8 families, 25% to 100% αIIbβ3). For one patient (GT76) 
αIIbβ3 was not assessed. Symptoms included epistaxis, easy bruising, hematomas, 
ecchymoses, petechiae, gingivorrhagia, post-invasive bleeding, heavy bleeding at menarche 
and/or menometrorrhagia; 23 patients (28%) had experienced GI bleeding (often a major 
problem in later life). Hemarthroses and intracranial bleeding were very rare. Details of 
treatment were unavailable for 6 patients while 8 patients had received no treatment or were 
restricted to anti-fibrinolytics or local measures. A large majority of patients for whom details 
were available had received one or more transfusions of platelet (74%) or RBC (70%) 
concentrates and/or rFVIIa (39%) in response to heavy bleeding or as a preventive measure 
prior to surgical trauma or childbirth. While most patients exhibited bleeding from early age, 
GT was occasionally diagnosed late in life with bleeding first occurring after trauma or, for 
women, at childbirth. Variability was seen even within the same family (see GT36a-c). Each 
patient was retrospectively assigned a bleeding score (1 to 4) according to WHO guidelines 
(see Section genotype/phenotype correlations).  
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Patients’ genotype 
Supp. Table S2 identifies sequencing variants absent from the NIH dbSNP database and 
considered candidates causal of GT by computer-based algorithms or following in vitro 
testing. A second sequencing and/or HRM analysis confirmed each variation after a new PCR 
amplification from DNA of the propositus and/or family members. The wide distribution of 
mutations across both genes is shown in Fig. 1 and their relative proportion by type in Supp. 
Fig. S1 (part A). Splice site, frameshift (and small deletions or duplications), missense and 
nonsense mutations were all common. Of the 78 different genetic variants, 55 were novel to 
this study; previously reported mutations are referenced in Supp. Table S3. When possible, 
segregation of mutations in affected families was confirmed by HRM analysis or direct 
sequencing; HRM is illustrated for the parents of GT41 in Supp. Fig. S2. Of the above 
mutations, eleven were repeated at least once among the 76 families included in our study 
(Fig. 1). 
Homozygous mutations occurred in 27 of the 76 families (16 affecting ITGA2B and 
11 ITGB3) for which a high proportion (63%) associated with consanguinity (not known for 
two families). Included are two siblings of a Moroccan family (GT43a and b) homozygous 
for c.614+1G>T splice and c.683G>A (p.Arg228His) variants of ITGB3. HRM analysis and 
sequencing confirmed that each parent carried the two mutations on a single allele. This 
family is from a remote region in Morocco and inbreeding over generations is highly 
probable. A total of 30 families showed compound heterozygosity (affecting ITGA2B for 20 
patients and ITGB3 for 10 patients). Two families (GT3 and GT35) had three potential 
damaging heterozygous mutations while GT35 had potentially damaging mutations in both 
genes. Sequencing identified only a single heterozygous mutation in 7 families (5 ITGA2B 
and 2 ITGB3). These included 4 patients with platelets expressing <5% αIIbβ3, one with type 
II GT and two patients with possible variant GT (GT4 and GT73). No mutations were located 
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for 12 patients including 7 whose platelets had <5% αIIbβ3 expression and 5 whose 
phenotype suggested variant GT (GT2, GT16, GT17, GT29 and GT46).   
Two patients from Bordeaux, for whom PCR-SSCP screening had previously 
identified single heterozygous mutations: GT9: ITGB3, p.Leu222Pro (L196P in classic 
numbering for the mature protein) and GT10: ITGA2B, p.Arg1026Gln (R996Q) [Peyruchaud 
et al. 1998; Nurden et al. 2002]; were now shown as compound heterozygotes for mutations 
in ITGB3 and ITGA2B respectively, thereby underlining the relative inefficiency of PCR-
SSCP for mutation detection.  
 
Missense mutations 
Of the 22 missense mutations affecting ITGA2B, 13 concerned the αIIb N-terminal β-
propeller encoded by exons 1 to 13, with 2 in the thigh domain, 6 in the membrane proximal 
calf-1 and calf-2 domains and 1 previously identified mutation in the cytoplasmic domain 
(Fig. 1; Supp. Fig S1). Of the 16 missense mutations affecting ITGB3, all were extracellular 
with 4 in the N-terminal PSI and hybrid domains, 7 in the βI domain and 4 in the EGF 
domains while 1 localized to the signal peptide. 
(a) Mutations affecting the β-propeller region of αIIb.  Our results confirm that 
missense mutations modifying the β-propeller of αIIb are a frequent cause of GT. Of the 13 
that we located in this region, 8 were novel (Fig. 1, Supp. Table S2). Most affected were the 
highly conserved structures. Homozygous amino acid substitutions included p.Gly201Ser 
common to two families from Argentina (GT52, GT58) and p.Arg358His in a French patient 
(GT26) that re-appeared in heterozygous form in a German family (GT11). Heterozygous 
missense mutations in the β-propeller were associated with other missense mutations in the β-
propeller, in the calf-2 domain, or with splice site mutations or frameshifts. Three families 
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with β-propeller mutations had type II GT with significant residual αIIbβ3 expression (GT11, 
GT18 and GT55) while the remainder had type I GT with <5% αIIbβ3.  
Figure 2 highlights structural modifications induced by selected novel amino acid 
substitutions in β-propeller conserved motifs. It is noteworthy that p.Gly44Val (G13V), 
p.Gly201Ser (G170S), p.Ala216Val (A185V) and p.Gly321Trp (G290W) all affect FG-GAP 
motifs modifying β-propeller structure at the interface with β3. The p.Gly44Val change in 
blade 7 causes steric interference between the first two β-strands leading to their separation 
(shown at increased resolution in Supp. Fig. S3 parts A,B); the tight interaction between these 
two β-strands is important for the locking of the β-propeller structure. It may also disrupt 
Ca2+-binding and potentially affect N-glycosylation at Asn46 (N15). Molecular dynamics 
simulations confirmed increased instability of the substituted αIIb β-propeller, with a 
dramatic Ca2+-dependent increase of RMSD (Supp. Fig. S3 part C). The changes caused a 
block in αIIbβ3 biosynthesis; WB confirmed the absence of αIIb in platelets (Supp. Table 
S1). The p.Gly201Ser (G170S), p.Ala216Val (A185V) and p.Gly321Trp (G290W) 
substitutions influence H-bonding and blade structure. Hydrophobic amino acids are enriched 
in the blades, notably for the central antiparallel β-sheet. The exclusion of water molecules 
protects lateral H-bonds that bind and organize the four anti-parallel β-sheets. The 
p.Val286Asp (V255D) substitution introduces a polar structure in this hydrophobic 
environment, promoting destabilization by opening the angle between blades 3 and 4 (Fig. 2). 
Water molecules enter and competitively form H-bonds with oxygen atoms or NH2-groups of 
constituent amino acids and disrupt structure. The p.Val420Ala (V389A) change promotes 
destabilization by pushing apart blades 6 and 7 (not illustrated). In contrast, p.Gly401Cys 
(G370C) alters local electrostatic potential and affects a Ca2+-binding loop by disrupting a H-
bond with a nearby Asp in a conserved motif that binds Ca2+. 
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 (b) Mutations affecting the αIIb thigh and calf domains. Eight missense mutations in 
our cohort affect these domains (Fig. 1), of these only p.Gln626His (Q595H), p.Cys705Arg 
(C674R), and p.Val934Phe (V903F) are known (Supp. Table S3). In our cohort, p.Val934Phe 
was heterozygous in a type II French patient (GT18) where it combines with p.Gly401Cys. It 
also occurs as the only affected allele in a second French patient with 10-20% residual αIIbβ3 
(GT20) pointing to the presence of a second as yet undiscovered genetic defect. All other 
patients in this cohort had type I GT. The substitution p.Cys705Arg in a type II patient 
(GT49) was originally described in a Spanish type II GT patient where it disrupted an 
intramolecular Cys705-Cys718 disulfide blocking pro-αIIbβ3 maturation [Gonzalez-
Manchon et al., 1999]. Molecular modeling is illustrated in Fig. 3 for the novel p.Gly823Glu 
(G792E), p.Leu955Gln (L924Q), and p.Thr984Lys (T953K) mutations located in GT27, 
GT21 and GT72 respectively. Gly823 (G792) is found between calf-1 and calf-2 in an 
unstructured connecting loop between two adjacent β sheets. The larger negatively charged 
Glu increases the angle between the two domains by pushing away the connecting ribbon 
between calf-1 and calf-2 with a straightening of the second distal part of the long arm of 
αIIb. In vitro mutagenesis confirmed a reduced surface expression with wild-type β3 in COS-
7 cells and a high proportion of intracellular pro-αIIbβ3 in the cells (data not shown). The 
p.Leu955Gln (L924Q) and p. Thr984Lys (T953K) substitutions are adjacent to a conserved 
calf-2 sequence consisting of five polar amino acids orientated towards the inside of the β-
barrel structure of calf-2 and held in place by H-bonds; they introduce steric encumbrance 
breaking H-bonds with loss of rigidity within the calf-2 structure.  
 (c) Mutations within exons of ITGA2B interfering with splicing. Included among the 
missense mutations are homozygous p.Gln626His (GT69) and heterozygous p.Phe191Val 
(GT57) substitutions; however, the causative nucleotide transitions within exons 18 and 4 
respectively are predicted to interfere with splicing. The c.1876G>C (p.Gln626His) transition 
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was shown to result in skipping of exon 18 by Jallu et al. [2010] and was not studied further. 
The c.571T>G (p.Phe191Val) mutation is novel and NNSPLICE no longer identified the 
normal donor splice site of intron 4 in the mutant; all prediction tools found a new potential 
splice site 4 bp upstream of the natural donor splice site in intron 4 with elevated scores (SSF, 
75.45; NNSPLICE, 0.75; HSF, 82.35). We confirmed this prediction by expressing a mutated 
minigene covering this region in COS-7 cells. While PCR amplification showed similar sized 
products for the wild type and mutated fragment (Fig. 4 panel A), sequencing revealed that 
the most common mutated transcript contained a four bp deletion (TTTA) that introduced a 
frameshift and a premature stop codon after 39 amino acids. 
(d) Missense mutations affecting β3. A total of 15 missense mutations occurred in the 
extracellular domains of β3 while another (p.Trp11Arg) (found in GT62) affected the signal 
peptide (Fig. 1; Supp. Table S2). Six homozygous mutations all associated with type I GT 
while heterozygous mutations occurred in families with type I, type II or variant GT. The 
majority of the β3 missense mutations are novel: only p.Arg119Gln (R93Q), p.Leu222Pro 
(L196P), p.Cys601Arg (C575R) and p.Cys624Tyr (C598Y) have been previously reported. 
The physiologic importance of p.Arg119Gln (GT53) that also disrupts the HPA-1a epitope is 
controversial [Watkins et al., 2002; Peretz et al., 2006].  
A novel heterozygous p.Arg63Cys (R37C) substitution in the PSI domain in a type II 
French patient (GT7) is of interest. This polar amino acid is adjacent to Cys39 (C13) in the 
PSI domain; Cys39 (C13) forms a long-range disulfide to Cys461 (C435) in the EGF-1 
domain while the nearby Cys52 (C26) is linked to Cys75 (C49). The introduction of Cys63 
introduces less steric encumbrance and possible disulfide exchange with nearby cysteines, 
most probably with Cys52 in view of its close proximity, a rearrangement that would destroy 
a loop essential for the hybrid domain structure (Fig. 5). To confirm the effect of p.Arg63Cys 
on the biogenesis of αIIbβ3, we transiently expressed mutant integrin in COS-7 cells. FACS 
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analysis showed 85% reduction of αIIbβ3Cys63 expression on transfected cells compared to 
wild type (Supp. Fig. S4). Immunoblotting of lysed cells showed a conspicuous presence of 
pro-αIIb and mature αIIb was reduced implying a slow or impaired αIIbβ3 complex 
maturation in this type II patient. 
Two novel mutations affected the hybrid domain composed of β-sheets forming a β-
barrel structure, the bulk of the hydrophobic amino acids orientating towards the interior (Fig. 
5). Molecular modeling predicted that p.Leu118His (L92H) located in GT3 introduces 
instability not only through increased steric encumbrance but also by perturbing the 
hydrophobic environment. Arg131 (R105) (GT35a, b) is at the apex of a β-strand on the 
upper edge of the hybrid domain. The introduction of a Pro introduces a bend just before the 
segment that joins the βI domain. We detected 4 novel mutations in the βI domain (Fig. 5). 
The p.Pro189Ser (P163S) change, previously studied by us [Laguerre et al., 2013], influences 
Arg287 (Arg261), an amino acid of β3 that penetrates deep within the core of the αIIb β-
propeller. Homozygous in a type I French patient (GT12), p.Pro189Ser is associated with a 
frameshift mutation in a second unrelated type I French patient (GT5). Homozygous 
p.Asp314Tyr in another type I patient (GT6) acts directly on the small β-helix 3-10 carrying 
Arg287. The p.Gly297Arg (G271R) substitution (GT73) introduces steric encumbrance at the 
interface between the αIIb and β3 headpieces. A homozygous p.Tyr344Ser (Y318S) mutation 
in GT23 with type I GT is localized near the β3 MIDAS site and adjacent to Asp277 (D251), 
Tyr344 forming a H-bond with an oxygen atom of the main chain of Asp277. Replacement of 
Tyr344 by the smaller Ser causes the loss of this H-bond rendering the segment containing 
the MIDAS and SyMBS sites less stable.  
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GT9 with type II GT and αIIbβ3 expression that almost borderlines with variant GT 
combines a previously reported heterozygous p.Leu222Pro (L196P) substitution with a 
second previously described activating β-propeller p.Cys624Tyr (C598Y) mutation that after 
transfection in CHO cells severely reduced but did not abrogate 3 expression [Chen et al., 
2001; Nurden et al., 2002].  
A heterozygous p.Asp578Asn mutation (GT3) caused by a nucleotide transition in 
exon 11 occurs after a two bp del in exon 5 of the same allele. Sequencing and HRM analyses 
for the patient’s daughter confirmed their heterozygous presence on a single allele. As the 
latter is predicted to give a frameshift followed by a premature stop codon, the missense 
mutation may be an innocent bystander. The same remark applies to p.Arg228His in exon 5 
that co-expressed with a c.614+1G>T transition affecting the splice site of exon 4 in the 
Moroccan family (GT43) with two linked homozygous mutations.  
 
Splice site variations, frameshifts and stop codons 
Stop codons leading to truncated subunits, often associated with nonsense-mediated decay 
were abundant (8 in ITGA2B and 2 ITGB3) but have been largely studied in GT [Peretz et al, 
2006; Jallu et al. 2010] and were not explored further by us. A total of 15 different genetic 
variants affected intronic splice sites with 9 in ITGA2B (7 novel) and 7 in ITGB3 (7 novel) 
(Supp. Table S2, Supp. Fig. S1). These included c.1544+1G->A at the splice donor site of 
intron 15 of ITGA2B, a mutation characteristic of the French Manouche gypsy tribe [Schlegel 
et al., 1995; Fiore et al., 2011]. This results in a premature stop codon leaving αIIb truncated 
before the transmembrane domain and type I GT. Two gypsy patients in our cohort (GT19, 
GT24) were homozygous for this mutation. A third (GT4) combined heterozygous expression 
with 50% platelet αIIbβ3 that proved nonfunctional due to a homozygous FERMT3 (encoding 
kindlin-3) mutation [Robert et al., 2011]. Other mutation types in noncoding regions gave rise 
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to frameshifts (7 ITGA2B, 7 ITGB3) following small deletions or duplications and there was 
1 UTR mutation.  Splice site variations or insertion/deletion mutations mostly resulted in 
frameshifts and premature stop codons; exceptions are the in-frame variants seen for GT8 
(presented below), GT15, GT38 and GT45, and two already known mutations found for 
GT50 and GT69. Exon skipping was predicted for the homozygous c.1879-2A>G (GT66, 
exon 19), c.2348+5G>C (GT8, exon 23) and the heterozygous c.574+1G>A (GT65, exon 4) 
variants of ITGA2B; and for the homozygous (c.614+1G>T (GT43, exon 4), c.777+1G>A 
(GT30, exon 5), c.613_614+2del (GT70, exon 4), and the heterozygous c.940-2A>G (GT38, 
exon 7) and c.2014+5G>A (GT54, exon 12) variants of ITGB3 (Supp. Table S2). Two 
mutations were explored in more detail. 
(i) A 13 bp del within intron 14 of ITGA2B. Intriguingly the most recurrent noncoding 
mutation is a heterozygous c.1440-13_c.1440-1del within intron 14 of ITGA2B in 7 families 
(Supp. Table S2). As these include patients from different countries with no obvious ancestral 
link, the most probable cause is a mutational hotspot although this is not readily apparent. To 
confirm activation of a cryptic splice site [Pillois et al., 2012], splicing patterns associated 
with this 13bp del were evaluated using the hybrid minigene transfection assay in COS-7 
cells (Fig. 4). Results confirmed a new cryptic 5’ splicing site and a 2-bp deletion within the 
mRNA. This induced a reading-frame shift and a premature stop codon after 105 aberrant 
amino acids. The abnormal mRNA produced is predicted to be a target for nonsense-
mediated decay.   
(ii) In vitro analysis of the c.2348+5G>C transversion in ITGA2B. Splicing tools 
predicted this variation in intron 23 of a type II patient (GT8) to result in the loss of a native 
splice site and skipping of exon 23, while maintaining the open reading frame. In all cases 
there was a loss or significant reduction of the splicing score of the natural splice donor site 
of exon 23 (SSF, 81 to 0; NNSPLICE, 0.63 to 0; Genesplicer 6.91 to 3.53 and HSF, 90.69 to 
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78.53). Skipping of exon 23 was confirmed experimentally using the hybrid minigene 
transfection assay (Fig. 4). Furthermore, using real-time PCR and primers specific for exons 
22 and 23 or exon 22 to 24, we showed major quantitative changes in the expression of the 
spliced mRNAs (Supp. Fig. S5). A small residual expression of the normal transcript using 
primers for exon 22-23 may explain the residual αIIbβ3 on the platelet surface. Exon 23 
codes for residues 756–783 of the αIIb subunit. To confirm the effect of this deletion on 
αIIbβ3 synthesis, we co-transfected an αIIb-ΔE23 cDNA construct into COS-7 cells with 
normal β3 cDNA. WB showed that cells transfected with normal αIIb displayed both pro-αIIb 
and mature αIIb, those transfected with αIIb-ΔE23 only expressed the mutated immature 
protein and there was no surface expression of mutated αIIbβ3 (Supp. Fig. S4).  
A homozygous mutation (c.165T->C) mutation affecting the 3’-UTR of ITGA2B in a 
French patient of African origin with type I GT was not studied further as the patient (GT75) 
was no longer available. 
 
Large gene deletions or rearrangements 
A feature of our study was the search for large gene deletions or rearrangements in patients 
for whom single heterozygous or no gene mutations were detected by Sanger sequencing. 
The results are given in Supp. Table S2. Single allele deletions of exons 5 and 6 (GT45) and 
of exons 23 to 29 (GT68) were detected in ITGA2B while a deletion of exons 14 and 15 
(GT54) was found in ITGB3. A homozygous duplication of exons 3-12 was also detected in 
ITGA2B of a Syrian patient (GT28). We also examined patients for whom homozygous 
mutations were found in the absence of reported consanguinity but no large gene deletions or 
rearrangements were found in this group.  
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Genotype/phenotype correlations 
A preliminary examination of a breakdown of WHO bleeding score with respect to GT type 
showed a greater tendency for type I patients to have a higher bleeding score with respect to 
type II and the predicted variants who as groups tended to have a milder bleeding syndrome 
(Table 1). Notwithstanding, the number of type II patients remained small while the majority 
of patients predicted to have variant GT failed to genotype for ITGA2B or ITGB3 defects in 
our study. Interestingly, for fully genotyped patients in the type I subgroup, bleeding severity 
was independent of the nature of the affected gene or of the type of mutation. 
 
Discussion 
 
Adapting the nomenclature of George et al. [1990], we classified patients into type I (<5% 
αIIbβ3), type II (5-25% αIIbβ3) or variants (>25% αIIbβ3). Only one patient (GT76) was 
included on the basis of a total absence of platelet aggregation alone. Sanger sequencing of 
ITGA2B or ITGB3 provided an explanation for the GT phenotype in 57 families; 7 families (4 
type I, 1 type II and 2 potential variants) had a single heterozygous mutation in ITGA2B or 
ITGB3 and 12 families no mutations (7 type I and 5 potential variants). Of the 78 causative 
genetic variants, 55 were novel, confirming how outside ethnic groups most families possess 
their own private mutation. Novel heterozygous large deletions concerning two or more 
exons were subsequently detected by quantitative real-time PCR in 3 patients for whom a 
single heterozygous mutation had been revealed by Sanger sequencing; while a large 
homozygous duplication was located for GT28, a Syrian man with type I GT thus raising to 
61 the families (80% of the total) for whom genotyping was successful. Previously, an 
inversion-deletion detected by Southern blot in a Mexican family with type I GT was linked 
to homologous recombination of intragene Alu sequences in ITGB3 [Li and Bray, 1993]. 
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Otherwise, reports of large deletions in ITGA2B or ITGB3 are rare [Burk et al., 1991; Djaffar 
et al., 1993; Rosenberg et al., 1997]. Explanations for unsuccessful genotyping include 
defects (a) in non-sequenced intronic and upstream promoter regions, (b) of miRNA 
regulating αIIbβ3 synthesis and (c) in other genes that code for proteins necessary for αIIbβ3 
synthesis or function. 
Two patients with variant forms but with single or no mutations in ITGA2B or ITGB3 
were investigated further [Robert et al., 2011; Canault et al., 2014]. GT4 had heterozygous 
expression of the c.1544+1G>A French gypsy splice mutation but no platelet aggregation, 
results that contrast with obligate heterozygotes in GT where 50% αIIbβ3 expression allows 
normal platelet function [George et al., 1990]. As a moderate immune deficiency was 
associated with the severe bleeding phenotype, FERMT3 responsible for leukocyte adhesion 
deficiency type III (LAD-III) was sequenced [Robert et al., 2011]. A novel homozygous A>C 
transversion in the exon 3 acceptor splice site of FERMT3 led to a frameshift and a stop 
codon; a confirmed absence of kindlin-3 in platelets rendered the residual αIIbβ3 
nonfunctional. For GT2, exome sequencing revealed a nonsynonymous c.G742T transversion 
in RASGRP2 giving a p.Gly248Trp substitution in the CALDAG-GEFI signaling protein. In 
vitro expression showed a nonfunctional protein and a block in the Rap1-dependent 
activation pathway of αIIbβ3 but normal leukocyte function [Canault et al., 2014]. Genes 
involved in integrin-related signaling pathways clearly represent a previously unrecognized 
cause of variant GT and must be taken into account when considering phenotype. 
     Homozygous or compound heterozygous nonsense mutations all gave type I GT, 
findings compatible with a block in αIIbβ3 biogenesis and a high probability of nonsense-
mediated mRNA decay [Vinciguerra et al., 1996; Arias-Salgado et al., 2002; Peretz et al., 
2006; Jallu et al., 2010]. A specific example is the homozygous ITGA2B exon 19 c.1882C>T 
transition common to two Swiss siblings (GT39a/b) with type I GT. The result is a stop at 
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Arg628* (R597*), a mutation previously proven in a Spanish patient to prevent αIIbβ3 
complex expression [Arias-Salgado et al., 2002]. The differing bleeding scores for the Swiss 
siblings emphasize how factors other than αIIbβ3 deficiency influence bleeding severity. 
Mutations affecting splice sites were abundant, concerned both genes and gave type I or type 
II GT. The c.1440-13_c.1440-1del in intron 14 of ITGA2B was enigmatic. Detected in 7 
families spanning 3 European countries, the affected patients included all 3 siblings of a 
Catalan family (GT36) thus proving its inheritance. We confirmed experimentally that the 
use of a cryptic splicing site led to a 2-bp deletion within mRNA, a reading-frame shift and a 
premature stop codon after 105 aberrant amino acids. The abnormal mRNA is also predicted 
to be a target for nonsense-mediated decay.  In all of our cases its presence segregates with a 
non-expressed allele. This 13-bp deletion is certainly that reported in patients from northwest 
France by Jallu et al. [2010] but who assigned it a slightly different nomenclature. The 
reasons for its repeated appearance in non-related European families or its restriction to a 
heterozygous state are unknown. It contrasts with a founder 13-bp in-frame deletion that is 
common in Palestinian–Arab patients and which leads to a deletion of 6 amino acids 
(Ala106-Gln111) within blade 2 of the αIIb propeller and a block in αIIbβ3 biogenesis 
[Rosenberg et al., 2005]. An interesting splice site mutation was the novel homozygous 
c.2348+5G>C transversion in ITGA2B in an elderly male type II patient (GT8) with severe 
bleeding in his youth and repeated GI bleeding in later life. In vivo experimentation allowed 
us to show that this mutation resulted in the skipping of exon 23 but that a small residual 
splicing of normal αIIb accounted for the residual αIIbβ3 in his platelets; significantly the 
presence of small amounts of αIIbβ3 did not protect against bleeding in his case.  
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We have highlighted 22 predicted damaging amino acid substitutions within αIIb and 16 in 
β3. A high proportion (13 with 9 novel) affect the αIIb β-propeller confirming earlier reports 
that many genetic variants causing GT disrupt this region [reviewed by Nelson et al., 2005; 
Mansour et al., 2011]. The β-propeller has 7 highly conserved blades each composed of 4 
anti-parallel β-strands connected by loops; side domains associate with the βI domain of β3 
while amino acid clusters on its upper surface contribute to ligand binding [Kamata et al., 
2001; Podolnikova et al., 2014]. A key structural role is played by conserved FG-GAP 
repeats in each blade. Four Ca2+-binding domains are present as part of β-hairpin loops 
extending from blades 4-7. Disease-causing β-propeller domain mutations either prevent pro-
αIIbβ3 formation or, for the majority, interfere with trafficking of pro-αIIbβ3 from the ER to 
the Golgi. As shown by our study, amino acid substitutions in the β-propeller domain give 
primarily type I with also, on occasion, type II GT.  
Our approach to β-propeller mutations was to look at the structural implications of 
novel amino acid substitutions highlighting those in conserved FG-GAP motifs. Molecular 
modeling showed how subtle changes and repositioning of side chains modified blade 
structure and H-bonding, particularly in domains affecting the interface with β3. Thus, the 
p.Gly44Val (GT39a-c) substitution in blade 7 disrupts β-sheet assembly, an instability that 
we confirmed experimentally by molecular dynamics simulations. The p.Gly44Val change 
may also interfere with N-glycosylation at Asn46, a key element in the binding of calnexin a 
chaperone, necessary for the transport of pro-αIIbβ3 to the Golgi apparatus [Mitchell et al., 
2006]. The p.Gly201Ser change (GT52) disrupts H-bonding and is adjacent to a previously 
reported p.Phe202Cys substitution that causes loss of contact with β3Arg287 and prevents 
pro-αIIbβ3 formation [Rosenberg et al., 2004]. In contrast, p.Val286Asp (GT40) gives a more 
polar structure to the hydrophobic environment deep in theβ-propeller allowing entry of 
water molecules that form disruptive H-bonds. A p.Ile405Thr mutation (GT74) in the αIIb 
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Ca2+-binding domain, first characterized by Mitchell et al. [2003], creates increased 
electrostatic potential non-conductive for Ca2+ binding. A Ca2+-binding loop is also the site of 
a novel p.Gly401Cys substitution (GT18) with disruption of a H-bond between Gly401 and a 
conserved Asp residue involved in metal ion binding. It is clear from the above and other 
reported mutations that the β-propeller is highly sensitive to the quality control exercised in 
the ER where mutated pro-αIIb or pro-αIIbβ3 are degraded by the proteasome.  
 We identified 8 missense mutations in the αIIb calf and thigh domains where less is 
known about αIIb structure. Previous studies have shown how a small deletion-insertion in 
calf-2 and an in-frame skipping of exon 20 affecting calf-1 failed to prevent pro-αIIbβ3 
formation but interfered with maturation [Rosenberg et al., 2003]. Similar findings have been 
reported for a 21-amino acid deletion (Leu817-Gln837) in calf-2 and for p.Val982Met and 
p.His813Asn substitutions [Fujimoto et al., 2004; Nurden et al., 2004; Losonczy et al., 2007].  
We focused on novel p.Gly823Glu, p.Leu955Phe and p.Thr984Lys mutations in calf-2. All 
were heterozygous in association with an identified and proven null mutation. Two gave type 
I GT (<5% αIIbβ3) (GT21, GT72), while p.Gly823Glu occurred in a French patient (GT27) 
with type II GT and 10% residual αIIbβ3 and where expression studies confirmed an altered 
maturation of pro-αIIbβ3. In fact, the larger negatively charged Glu823 results in the 
straightening of the second distal part of the long arm of αIIb. The p.Leu955Phe and 
p.Thr984Lys substitutions in calf-2 occur at or adjacent to a conserved motif of five polar 
amino acids central to the β-barrel protected from water molecules and involved in H-bond 
interactions. Both mutations induce flexibility. Finally, just how αIIb is under tight quality 
control is nicely shown for p.Cys705Arg (C674R in the mature protein) (GT49) where 
previous studies have shown that the mutated αIIb is retained by the BiP chaperone in the ER 
[Arias-Salgado et al., 2001].  
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Previously characterized missense mutations affecting β3 include variant GT with 
normally or partially expressed αIIbβ3 that fails to bind ligands when activated [Loftus et al., 
1990; Bajt et al., 1992; Lanza et al., 1992].  In our study, missense mutations in β3 primarily 
interfered with αIIbβ3 biogenesis. A novel heterozygous p.Arg63Cys substitution in the N-
terminal PSI domain of a type II French patient (GT7) is adjacent to Cys39 that forms a long-
range disulfide with Cys461 in EGF-1 while nearby Cys52 joins with Cys75. Introduction of 
Cys at position 63 leads to possible disulfide exchange while in vitro expression studies 
showed altered pro-αIIbβ3 maturation.  Interestingly, p.Cys39Gly and disruption of its long-
range disulfide also gives GT [Peretz et al., 2006]. Clustered hybrid domain substitutions, 
p.Leu118His (GT3) and p.Arg119Gln (GT53), as well as p.Arg131Pro (GT35) all caused loss 
of αIIbβ3 expression with molecular modeling predicting changes in H-bonding. Specifically, 
the novel p.Arg131Pro on the upper edge of the hybrid domain introduces a bend just before 
the segment that joins the βI domain of β3.  
Mutations in βI were associated in their majority with type I or type II GT and one 
potential variant form. Of these, molecular modeling shows that a homozygous p.Tyr344Ser 
mutation in GT23 leads to loss of a H-bond with Asp277 that potentially affects the MIDAS 
and SyMBS sites although the result is a loss of αIIbβ3 expression and type I GT. Both 
p.Pro189Ser and p.Asp314Tyr giving type I GT destabilize β3Arg287 an amino acid that 
penetrates deep within the core of the αIIb β-propeller, a finding previously shown by us for 
p.Pro189Ser by molecular dynamics simulation [Laguerre et al., 2013]. The p.Leu222Pro 
substitution differed in that it was associated with type II GT (GT9), a patient whose platelets 
fail to bind Fg (or PAC-1) on activation or to support clot retraction [Nurden et al., 2002]. 
Other βI domain mutations in the literature giving type II GT can lead to residual αIIbβ3 with 
conserved function [Ambo et al., 1998; Jackson et al., 1998; Ward et al., 2000]. Quite clearly, 
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βI-domain mutations can have widely diverging quantitative and qualitative effects on αIIbβ3 
expression.  
Four missense mutations localized to the disulfide-rich β3 EGF-3 and EGF-4 
domains. Of these, p.Cys601Arg (GT60) disrupts a disulfide with Cys612; a mutation that 
was first characterized in type I GT in Italy [D’Andrea et al., 2002]. Disruption of EGF-
domain disulfides leads to abrogated expression or to reduced activated forms [Mor-Cohen et 
al., 2012]. First located in type II GT [Chen et al., 2001], the activating p.Cys624Tyr 
substitution re-occurred in type II GT9 in combination with the loss of function p.Leu222Pro 
and in this situation spontaneous Fg- or PAC-1 binding to platelets was not seen (Supp. Table 
S1). β3 missense mutations can abrogate expression of both αIIbβ3 and αvβ3 receptors or 
have differential effects [Tadokoro et al., 2002; Mor-Cohen et al., 2012]. Indeed, β3 
p.Pro189Ser common to GT5 and GT12 actually reinforces the interaction between αv and β3 
while giving type I GT [Laguerre et al., 2013]. Heterozygous β3 p.Gly297Arg was the only 
mutation detected in GT73, a French woman with a severe bleeding syndrome and an 
absence of platelet aggregation but qualitatively abnormal αIIbβ3 (Supp. Table S1). This 
patient has a supposed second mutation that remains elusive and whose identification will be 
necessary to fully understand her phenotype. 
The highly polymorphic nature of ITGB3 and to a lesser extent ITGA2B is shown by 
the 33 human platelet alloantigen (HPA) systems spread across their extracellular domains 
[Curtis & McFarland, 2013]. In addition to homozygous disease-causing mutations, two 
unrelated French families (GT44, GT50) showed heterozygous expression of ITGA2B 
p.Val868Met (V837M in the mature protein) (data not shown). In fact, p.Val868Met is a low-
frequency HPA that segregates with the HPA-3b allele [Peterson et al., 2014]. Low-
frequency HPAs must be excluded when genotyping GT patients. Isoantibody formation 
following blood transfusion or during pregnancy is a major risk in GT [George et al., 1990; 
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Gruel et al., 1994]. In the current study, antibodies to αIIbβ3 have been detected in 20 
patients (14 female, 6 male; Supp. Table S1). Of these, only one, a woman without children 
belonging to the French Manouche gypsy tribe (GT19) had not received platelet or RBC 
transfusions and the cause of her immunization remains unknown (Supp. Table S1). Eighteen 
of the immunized patients were type I GT reinforcing our recent conclusion from a smaller 
study that the risk of isoantibody formation is largely restricted to patients whose platelets 
lack αIIbβ3 on their surface [Fiore et al., 2012].  
Striking from our study is the conclusion that the bleeding severity for the fully 
genotyped type I patients is independent of the affected gene (Table 1). While the chances of 
a severe bleeding phenotype are greater for a type I patient, there were exceptions with both 
type II patients (e.g. GT8) and variants (e.g. GT4) with a lifelong disorder severely impairing 
quality of life. In this initial analysis of our data we used a simple WHO bleeding score 
questionnaire. We now plan to perform a more intense analysis of the clinical data taking 
more precisely into account such variables as the number of bleeding episodes and the age of 
the patient, the number of transfusions, the number of RBC concentrates and also the country 
of origin. We will also be able to include other type II patients and variants from outside our 
cohort to make for a more powerful statistical analysis of their phenotype severity. But it is 
already quite clear that GT contrasts, for example, with MYH9-related disease (MYH9-RD) 
where the MYH9 genotype is a major determinant of the clinical manifestations allowing a 
hierarchical prognostic model [Saposnik et al., 2014]. In MYH9-RD, mutations and 
deficiency or nonfunctioning of nonmuscle myosin IIA are variably associated with kidney 
disease, deafness and cataracts and their appearance and severity can vary with the location 
and nature of the causative mutation. In contrast, in GT despite the expression of β3 in many 
lineages, the primary phenotype remains mucocutaneous bleeding due to a loss of platelet 
function. Significantly, although GI bleeding is a major problem especially in later life, 10 
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affected patients had ITGA2B compared to 8 with ITGB3 defects suggesting that αvβ3 is not 
involved. Although residual integrin in type II GT may be protective, for some patients the 
αIIbβ3 may have retained only partial or no functional capacity. While in variant GT-like 
syndromes genes involved in regulating αIIbβ3 function may give specific phenotypes; the 
phenotypic variability in classic GT appears likely to depend on epidemiological and other 
genetic factors affecting coagulation or vascular pathways of hemostasis. Large studies such 
as ours will allow follow-up studies to identify these factors in genotyped families. 
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Figure 1.  Mutation spectrum for ITGA2B and ITGB3 in 76 GT families. Schematic 
representation of (I) ITGA2B cDNA and αIIb domain structure, in comparison with (II) 
ITGB3 cDNA and β3 domain structure. In parts a), nucleotide variants are designated a 
symbol according to their type and grouped to the nearest exon. In parts b), missense 
mutations are identified by a single letter amino acid code. They are assigned to the structural 
domains of each subunit. Asterisks indicate the number of times the variant was found in 
apparently unrelated families in our study. In red are two missense mutations in ITGA2B 
predicted for exonic variants that also influence splicing and a single mutation in ITGB3 
affecting the signal peptide. cDNA accession numbers for ITGA2B and ITGB3 are 
NM_000419.3 and NM_000212.2 respectively. UniProt accession numbers for αIIb and β3 
are P08514 and P05106 respectively. Amino acid numbering is according to HGVS 
nomenclature with +1 corresponding to the translation initiating methionine. Mutations 
giving rise to GT are widely distributed across both genes. 
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Figure 2. Ribbon diagrams highlighting selected novel missense mutations within the αIIb β-
propeller. The upper central panel shows the surface (front) of the propeller in contact with 
the βI domain of β3 and in the lower central panel we show the opposing side (back) of the 
propeller; red open circles localize the substituted amino acids that are identified in single 
letter code. Blade β-sheets are in pale blue, the FG-GAP motif in light green and Ca2+-
binding motifs in dark red. On the left side are enlarged views of the FG-GAP and Ca2+-
binding motifs with structuring H-bonds (dotted lines). Changes induced by p.Gly44Val, 
p.Gly201Ser, p.Ala216Val and p.Gly321Trp substitutions affecting FG-GAP motifs are 
shown in the upper windows. Val44 provokes steric encumbrance (red discs) predicted to 
break structuring H-bonds within the FG-GAP motif. Similar changes are predicted for 
p.Gly201Ser, p.Ala216Val and p.Gly321Trp. For the p.Val286Asp substitution (center panel) 
at the hydrophobic interior of the helix (blade 4), the introduced polar amino acid pushes 
apart the blades with entry of water molecules (blue spheres) that disrupt H-bonds and cause 
a major disturbance of β-propeller structure. Gly401 lies close to a calcium-binding motif 
given by 4 Asp residues within the third Ca2+-binding loop on the far side of the β-propeller 
(the calcium atom is shown as a gray sphere). Structural changes include a loss of H-bonds 
extending from the substituted Gly. Mutations are illustrated as graphical sticks, amino acid 
residues engaged in H-bonds are represented as sticks with C atoms in white, N atoms in 
blue, O atoms in red and S atoms in orange. Models were obtained using the PyMol 
Molecular Graphics System, version 1.3 and the 3 fcs pdb file.  
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Figure 3. Molecular representations of novel missense mutations within the αIIb calf-2 
domain. Central is a ribbon diagram depicting the αIIb arm with the thigh domain in slate 
blue, the calf-1 domain in blue and the calf-2 domain in dark blue. The p.Gly823Glu, 
p.Thr984Lys and p.Leu955Gln substitutions are shown as red open circles; inserts show 
graphical representations of mutations with C atoms in white, N atoms in blue, O atoms in 
red and S atoms in orange; graphical “bumps” (red discs) reveal steric encumbrance caused 
by the amino acid substitution. Amino acids engaged in hydrogen (H)-bonds (dotted lines) 
are shown as sticks. Specifically, Glu823 pushes away the connecting ribbon between calf-1 
and calf-2 resulting in an increased distance between Glu823 and Glu776, thereby opening 
the angle formed by calf-1 and calf-2 domains (left hand side windows). On the right hand 
side, windows illustrate the β-barrel structure of the calf-2 domain composed of 9 anti-
parallel β-sheets. p.Leu995Gln and p.Thr984Lys substitutions result in the loss of a motif 
composed of five polar amino acids (Tyr784, His782, Ser754, Ser926 and Thr953) sharing H-
bonds (dotted lines) within a largely hydrophobic region. Angle and distance measurements 
are indicated on the Figure. Hydrophobic lateral side-chains of β-sheet residues pointing 
inside the β-barrel structure of the calf-2 domain are in white. Models were obtained using 
the PyMol Molecular Graphics System, version 1.3 and the 3 fcs pdb file. 
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Figure 4. Minigene studies of mRNA splicing following transient expression of selected 
constructs in COS-7 cells. Illustrated are the results for genomic sequencing, agarose gel 
electrophoresis of the amplified minigene cDNA PCR products, and direct PCR cDNA 
fragment sequencing. A/ A heterozygous T to G change at c.571 in exon4 and close to its 
boundary with intron 4 of ITGA2B for GT57 gave rise to similarly migrating PCR products 
when wild type and mutant minigene constructs were transfected in COS-7 cells with a 4 bp 
deletion revealed on sequencing. B/ The heterozygous intron 14 c.1440-13_c.1440-1del 
found in the ITGA2B gene of 7 unrelated type I GT patients also gave normally migrating 
minigene PCR products. However, direct sequencing shows a 2 bp deletion and activation of 
an upstream cryptic splice site in exon 15 C/ A homozygous c.2348+5G>C transversion in 
intron 23 of a type II patient (GT8) gave rise to a smaller and faster migrating minigene PCR 
product; direct sequencing of the major transcript confirmed skipping of exon 23. 
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Figure 5. Structural changes induced by selected missense mutations within the β3 
extracellular domain. A ribbon diagram is shown in the center with the PSI domain in light 
green, the hybrid domain in green, the βI domain in dark green and the EGF-1 domain in 
green; red open circles situate the illustrated mutations. Residues of the active site SyMBS 
domain are represented as yellow sticks, those of the MIDAS domain in olive sticks and 
those of the adMIDAS domain as brown sticks. Ca2+ and Mg2+ atoms are shown as gray and 
pale blue spheres respectively. The p.Arg63Cys mutation (right lower panel) in the PSI 
domain is close to disulfides within the PSI or connecting PSI and EGF-1 domains. The 
introduced Cys63 is available to competitively interact with Cys52 or other nearby Cys 
residues, the result is pro-αIIbβ3 complex formation but a block in maturation (see Supp. Fig. 
S4). Both p.Arg131Pro and p.Leu118His are novel mutations within the hybrid domain. The 
p.Arg131Pro change results in a -turn in the connecting ribbon with the upper I domain. In 
contrast, p.Leu118His directly involves the -barrel structure of the hybrid domain 
(hydrophobic residues pointing to the interior are in white); it introduces a larger polar amino 
acid into the hydrophobic region with steric encumbrance. Both p.Asp314Tyr and 
p.Pro189Ser affect β3Arg287 (shown as dark green spheres in the insets), a β3 residue 
penetrating deep within the αIIb β-propeller. The p.Asp314Tyr substitution results in steric 
encumbrance that pushes away the small 3-10 helix bearing Arg287. The p.Gly297Arg 
substitution introduces steric encumbrance at the interface between αIIb and β3 headpieces. 
Tyr344 lies close to the metal coordination sites of the βI domain; its replacement by the 
smaller Ser results in loss of a structuring H-bond (dotted line) with Ala252 beside Asp251 of 
the MIDAS site. C atoms are colored in white, N atoms in blue, O atoms in red and S atoms 
in orange. Graphical “bumps” (red discs) indicate steric encumbrance. Amino acid residues 
engaged in H-bonds are shown as sticks. Disulfides are represented as lines. In the case of the 
p.Arg63Cys substitution, distance measurements separating Cys residues are indicated on the 
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figure. Models were obtained using the PyMol Molecular Graphics System, version 1.3 and 
the 3 fcs pdb file. 
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Table 1. Phenotype/Genotype correlations with respect to bleeding score 
 Total  Genotyped  Type I  Type I  
 I II var  I II var  ITGA2B ITGB3  missense other  
 (n) (n) (n) p (n) (n) (n) p (n) (n) p (n) (n) p 
WHO Bleeding score               
1 1 3 2 0.02* 1 2 1 0.022* 0 1 0.211 1 0 0.445 
2 17 2 1  16 2 0  12 4  9 7  
3 26 2 3  21 2 0  10 11  10 11  
4 19 2 2  18 2 0  11 7  6 12  
Total: All enrolled cases for whom clinical data was available. 
Genotyped: Patients with homozygous or composite heterozygous mutations in ITGA2B or ITGB3 genes. 
Type I: GT type I patients with homozygous or composite heterozygous mutations in ITGA2B or ITGB3 genes. 
*denotes statistical two sided Fisher's Exact Test significance. 
 
 
This article is protected by copyright. All rights reserved.   50 
 
 
Appendix: The authors also acknowledge the role of the following additional 
participants in patient recruitment and collecting data 
Dr. Ismaïl El Alamy, Laboratoire d'Explorations Fonctionnelles Plaquettaires,   Hôpital 
Tenon, Paris, France; Dr. Marie-Elizabethe Briquel, Service d'Hématologie-
Biologique,  Hôpital de Brabois,  CHU de Nancy,   Vandoeuvre-les-
Nancy,  France;  Professor Hervé Chambost, Service de Pédiatrie et Hématologie 
Pédiatrique, Hôpital de la Timone, Marseille, France; Dr. Ségolène Claeyssens, Service de 
Pédiatrie – Hématologie, Oncologie, CHU de Toulouse, Toulouse, France; Dr. Bénédicte 
Delahousse, Service d’Hématologie-Hémostase, Hôpital Trousseau, Tours, France; 
Professeur Ginès Escolar, Hospital Clinic, Servicio de Hemoterapia y Hemostasia, 
Barcelona, Spain; Dr. Remi Favier, Service d'Hématologie Clinique, Hôpital d'Enfants 
Armand-Trousseau, Paris, France; Dr. Michel Laguerre, Institut Européen de Chimie et 
Biologie, Pessac, France; Professor Thomas Lecompte, Hemostasis Unit and Haematology 
Department, University Hospital of Geneva, Geneva, Switzerland; Dr. Desiree Medeiros, 
Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, USA; Dr. Maguy 
Micheau, Service d’Hématologie Biologique, Hôpital Pellegrin, CHU Bordeaux, Bordeaux, 
France; Professor Philippe Moerloose, Haemostasis Unit, Geneva University Hospitals, 
Geneva, Switzeland; Professor Marta Pico, Servicia Hemostasia, Hospital Val d’Hebron, 
Barcelona, Spain; Dr. Catherine Pouymayou, Laboratoire d’Hématologie, Hôpital La 
Timone, Marseille, France; Dr. Markus Schmugge, Division of Haematology, University 
Childrens Hospital, Zürich, Switzerland; Dr. David Wilcox, Blood Research Institute, Blood 
Center of Wisconsin, Milwaukee, Wisconsin, USA. 
